Topical pravibismane as adjunctive therapy for moderate or severe diabetic foot infections: A phase 1b randomized, multicenter, double‐blind, placebo‐controlled trial

Overview of attention for article published in International Wound Journal, April 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 1,240)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 22 news stories from 22 outlets.

Topical pravibismane was found to be safe and well tolerated at all doses tested in subjects with moderately to severely…

Le pravibismane topique s’est révélé sûr et bien toléré pour toutes les doses testées chez des sujets souffrant d’ulcères du…

Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International…

Microbion Corporation Logo (CNW Group/Microbion Corporation) Share on FacebookShare on TwitterShare on Whatsapp Topical…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 18 additional news stories.